secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-09-09T11:05:05+00:00
Accession:  0001193125-26-385881
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology raises $50M for diabetes-focused subsidiary Caspian; retains ~49% stake
--------------------------------------------------------------------------------

- Caspian Therapeutics, a new wholly owned subsidiary, raised $50.0M in Series A preferred stock on Sept 8, 2026.
- Kura invested $4.3M; post-financing Kura holds ~49.2% of Caspian's outstanding capital stock.
- Kura contributed rights to next-gen menin inhibitors for diabetes/cardiometabolic diseases, incl. KO-7246, to Caspian.
- Kura granted Caspian non-exclusive licenses to ziftomenib-related patents/data; received reciprocal license for R&D.
- Caspian solely responsible for development/regulatory/commercialization in diabetes field; Kura provides services under agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/0001193125-26-385881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/d496500d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer